{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:11:56Z","timestamp":1791277916570,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,1,29]],"date-time":"2012-01-29T00:00:00Z","timestamp":1327795200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Chem Biol"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1038\/nchembio.775","type":"journal-article","created":{"date-parts":[[2012,1,29]],"date-time":"2012-01-29T18:07:09Z","timestamp":1327860429000},"page":"285-293","source":"Crossref","is-referenced-by-count":166,"title":["BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia"],"prefix":"10.1038","volume":"8","author":[{"given":"Oliver","family":"Hantschel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Warsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Eckelhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Kaupe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Grebien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay-Uwe","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Superti-Furga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Sexl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,1,29]]},"reference":[{"key":"BFnchembio775_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","volume":"22","author":"S Wong","year":"2004","unstructured":"Wong, S. & Witte, O.N. The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol. 22, 247\u2013306 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnchembio775_CR2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldman","year":"2003","unstructured":"Goldman, J.M. & Melo, J.V. Chronic myeloid leukemia\u2013advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451\u20131464 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnchembio775_CR3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo, T.G., Pendergast, A.M., Muller, A.J. & Witte, O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079\u20131082 (1990).","journal-title":"Science"},{"key":"BFnchembio775_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrd839","volume":"1","author":"R Capdeville","year":"2002","unstructured":"Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1, 493\u2013502 (2002).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnchembio775_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrc2126","volume":"7","author":"E Weisberg","year":"2007","unstructured":"Weisberg, E., Manley, P.W., Cowan-Jacob, S.W., Hochhaus, A. & Griffin, J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukemia. Nat. Rev. Cancer 7, 345\u2013356 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnchembio775_CR6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker, B.J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408\u20132417 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnchembio775_CR7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus, A. et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23, 1054\u20131061 (2009).","journal-title":"Leukemia"},{"key":"BFnchembio775_CR8","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","volume":"22","author":"NP Shah","year":"2003","unstructured":"Shah, N.P. & Sawyers, C.L. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22, 7389\u20137395 (2003).","journal-title":"Oncogene"},{"key":"BFnchembio775_CR9","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","volume":"112","author":"BJ Druker","year":"2008","unstructured":"Druker, B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 112, 4808\u20134817 (2008).","journal-title":"Blood"},{"key":"BFnchembio775_CR10","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","volume":"114","author":"FE Nicolini","year":"2009","unstructured":"Nicolini, F.E. et al. Epidemiological study on survival of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients with BCR-ABL T315I mutation. Blood 114, 5271\u20135278 (2009).","journal-title":"Blood"},{"key":"BFnchembio775_CR11","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1084\/jem.183.3.811","volume":"183","author":"N Carlesso","year":"1996","unstructured":"Carlesso, N., Frank, D.A. & Griffin, J.D. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl. J. Exp. Med. 183, 811\u2013820 (1996).","journal-title":"J. Exp. Med."},{"key":"BFnchembio775_CR12","doi-asserted-by":"publisher","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","volume":"271","author":"RL Ilaria Jr.","year":"1996","unstructured":"Ilaria, R.L. Jr. & Van Etten, R.A. P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271, 31704\u201331710 (1996).","journal-title":"J. Biol. Chem."},{"key":"BFnchembio775_CR13","first-page":"247","volume":"13","author":"K Shuai","year":"1996","unstructured":"Shuai, K., Halpern, J., ten Hoeve, J., Rao, X. & Sawyers, C.L. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13, 247\u2013254 (1996).","journal-title":"Oncogene"},{"key":"BFnchembio775_CR14","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1084\/jem.189.8.1229","volume":"189","author":"M Nieborowska-Skorska","year":"1999","unstructured":"Nieborowska-Skorska, M. et al. Signal transducer and activator of transcription (STAT)5 activation by BCR\/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR\/ABL and is required for leukemogenesis. J. Exp. Med. 189, 1229\u20131242 (1999).","journal-title":"J. Exp. Med."},{"key":"BFnchembio775_CR15","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1182\/blood-2005-08-3087","volume":"107","author":"M Scherr","year":"2006","unstructured":"Scherr, M. et al. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 107, 3279\u20133287 (2006).","journal-title":"Blood"},{"key":"BFnchembio775_CR16","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1182\/blood-2005-10-4110","volume":"107","author":"D Ye","year":"2006","unstructured":"Ye, D., Wolff, N., Li, L., Zhang, S. & Ilaria, R.L. Jr. STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood 107, 4917\u20134925 (2006).","journal-title":"Blood"},{"key":"BFnchembio775_CR17","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/blood-2005-09-3596","volume":"107","author":"A Hoelbl","year":"2006","unstructured":"Hoelbl, A. et al. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood 107, 4898\u20134906 (2006).","journal-title":"Blood"},{"key":"BFnchembio775_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/emmm.201000062","volume":"2","author":"A Hoelbl","year":"2010","unstructured":"Hoelbl, A. et al. Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia. EMBO Mol. Med. 2, 98\u2013110 (2010).","journal-title":"EMBO Mol. Med."},{"key":"BFnchembio775_CR19","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","volume":"117","author":"W Warsch","year":"2011","unstructured":"Warsch, W. et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 117, 3409\u20133420 (2011).","journal-title":"Blood"},{"key":"BFnchembio775_CR20","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/0092-8674(94)90357-3","volume":"76","author":"K Shuai","year":"1994","unstructured":"Shuai, K. et al. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 76, 821\u2013828 (1994).","journal-title":"Cell"},{"key":"BFnchembio775_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-1119(02)00398-0","volume":"285","author":"T Kisseleva","year":"2002","unstructured":"Kisseleva, T., Bhattacharya, S., Braunstein, J. & Schindler, C.W. Signaling through the JAK\/STAT pathway, recent advances and future challenges. Gene 285, 1\u201324 (2002).","journal-title":"Gene"},{"key":"BFnchembio775_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.gde.2006.12.009","volume":"17","author":"JN Ihle","year":"2007","unstructured":"Ihle, J.N. & Gilliland, D.G. Jak2: normal function and role in hematopoietic disorders. Curr. Opin. Genet. Dev. 17, 8\u201314 (2007).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"BFnchembio775_CR23","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1038\/leu.2008.233","volume":"22","author":"R Kralovics","year":"2008","unstructured":"Kralovics, R. Genetic complexity of myeloproliferative neoplasms. Leukemia 22, 1841\u20131848 (2008).","journal-title":"Leukemia"},{"key":"BFnchembio775_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ccr.2009.10.015","volume":"16","author":"M Hedvat","year":"2009","unstructured":"Hedvat, M. et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16, 487\u2013497 (2009).","journal-title":"Cancer Cell"},{"key":"BFnchembio775_CR25","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/sj.leu.2402260","volume":"15","author":"N Miyamoto","year":"2001","unstructured":"Miyamoto, N. et al. The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome. Leukemia 15, 1758\u20131768 (2001).","journal-title":"Leukemia"},{"key":"BFnchembio775_CR26","doi-asserted-by":"publisher","first-page":"6188","DOI":"10.1038\/sj.onc.1204834","volume":"20","author":"S Xie","year":"2001","unstructured":"Xie, S. et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 20, 6188\u20136195 (2001).","journal-title":"Oncogene"},{"key":"BFnchembio775_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/leu.2010.287","volume":"25","author":"A Samanta","year":"2011","unstructured":"Samanta, A. et al. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia 25, 463\u2013472 (2011).","journal-title":"Leukemia"},{"key":"BFnchembio775_CR28","doi-asserted-by":"publisher","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-06-0025","volume":"66","author":"AK Samanta","year":"2006","unstructured":"Samanta, A.K., Lin, H., Sun, T., Kantarjian, H. & Arlinghaus, R.B. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 66, 6468\u20136472 (2006).","journal-title":"Cancer Res."},{"key":"BFnchembio775_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/leu.2010.269","volume":"25","author":"A Pardanani","year":"2011","unstructured":"Pardanani, A. et al. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 25, 218\u2013225 (2011).","journal-title":"Leukemia"},{"key":"BFnchembio775_CR30","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/sj.leu.2404750","volume":"21","author":"A Pardanani","year":"2007","unstructured":"Pardanani, A. et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L\/K mutations. Leukemia 21, 1658\u20131668 (2007).","journal-title":"Leukemia"},{"key":"BFnchembio775_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","volume":"13","author":"G Wernig","year":"2008","unstructured":"Wernig, G. et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13, 311\u2013320 (2008).","journal-title":"Cancer Cell"},{"key":"BFnchembio775_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ccr.2008.02.017","volume":"13","author":"I Geron","year":"2008","unstructured":"Geron, I. et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 13, 321\u2013330 (2008).","journal-title":"Cancer Cell"},{"key":"BFnchembio775_CR33","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1128\/MCB.24.12.5510-5520.2004","volume":"24","author":"K-U Wagner","year":"2004","unstructured":"Wagner, K.-U. et al. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol. Cell. Biol. 24, 5510\u20135520 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"BFnchembio775_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","volume":"93","author":"H Neubauer","year":"1998","unstructured":"Neubauer, H. et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397\u2013409 (1998).","journal-title":"Cell"},{"key":"BFnchembio775_CR35","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/onc.2009.7","volume":"28","author":"AK Samanta","year":"2009","unstructured":"Samanta, A.K. et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A\u2013SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 28, 1669\u20131681 (2009).","journal-title":"Oncogene"},{"key":"BFnchembio775_CR36","doi-asserted-by":"publisher","first-page":"6724","DOI":"10.1038\/sj.onc.1210757","volume":"26","author":"SJ Baker","year":"2007","unstructured":"Baker, S.J., Rane, S.G. & Reddy, E.P. Hematopoietic cytokine receptor signaling. Oncogene 26, 6724\u20136737 (2007).","journal-title":"Oncogene"},{"key":"BFnchembio775_CR37","doi-asserted-by":"publisher","first-page":"9018","DOI":"10.1128\/MCB.20.23.9018-9027.2000","volume":"20","author":"RA Blake","year":"2000","unstructured":"Blake, R.A. et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol. Cell. Biol. 20, 9018\u20139027 (2000).","journal-title":"Mol. Cell. Biol."},{"key":"BFnchembio775_CR38","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix, U. et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and non-kinase targets. Blood 110, 4055\u20134063 (2007).","journal-title":"Blood"},{"key":"BFnchembio775_CR39","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/leu.2008.334","volume":"23","author":"LL Remsing Rix","year":"2009","unstructured":"Remsing Rix, L.L. et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 23, 477\u2013485 (2009).","journal-title":"Leukemia"},{"key":"BFnchembio775_CR40","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1002\/j.1460-2075.1994.tb06756.x","volume":"13","author":"F Gouilleux","year":"1994","unstructured":"Gouilleux, F., Wakao, H., Mundt, M. & Groner, B. Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J. 13, 4361\u20134369 (1994).","journal-title":"EMBO J."},{"key":"BFnchembio775_CR41","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/sj.onc.1200885","volume":"14","author":"R de Jong","year":"1997","unstructured":"de Jong, R., ten Hoeve, J., Heisterkamp, N. & Groffen, J. Tyrosine 207 in CRKL is the BCR\/ABL phosphorylation site. Oncogene 14, 507\u2013513 (1997).","journal-title":"Oncogene"},{"key":"BFnchembio775_CR42","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/373536a0","volume":"373","author":"Z Songyang","year":"1995","unstructured":"Songyang, Z. et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373, 536\u2013539 (1995).","journal-title":"Nature"},{"key":"BFnchembio775_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/sj.leu.2404948","volume":"22","author":"A Pardanani","year":"2008","unstructured":"Pardanani, A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22, 23\u201330 (2008).","journal-title":"Leukemia"},{"key":"BFnchembio775_CR44","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama, A. et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109\u20133117 (2010).","journal-title":"Blood"},{"key":"BFnchembio775_CR45","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1038\/leu.2008.56","volume":"22","author":"TL Lasho","year":"2008","unstructured":"Lasho, T.L. et al. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 22, 1790\u20131792 (2008).","journal-title":"Leukemia"},{"key":"BFnchembio775_CR46","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.cell.2010.08.023","volume":"142","author":"WA Lim","year":"2010","unstructured":"Lim, W.A. & Pawson, T. Phosphotyrosine signaling: evolving a new cellular communication system. Cell 142, 661\u2013667 (2010).","journal-title":"Cell"},{"key":"BFnchembio775_CR47","doi-asserted-by":"publisher","first-page":"7414","DOI":"10.1073\/pnas.0900653106","volume":"106","author":"M Brehme","year":"2009","unstructured":"Brehme, M. et al. Charting the molecular network of the drug target Bcr-Abl. Proc. Natl. Acad. Sci. USA 106, 7414\u20137419 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnchembio775_CR48","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1038\/onc.2010.331","volume":"29","author":"B Titz","year":"2010","unstructured":"Titz, B. et al. The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization. Oncogene 29, 5895\u20135910 (2010).","journal-title":"Oncogene"},{"key":"BFnchembio775_CR49","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","volume":"117","author":"EA Nelson","year":"2011","unstructured":"Nelson, E.A. et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 117, 3421\u20133429 (2011).","journal-title":"Blood"},{"key":"BFnchembio775_CR50","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","volume":"112","author":"O Hantschel","year":"2003","unstructured":"Hantschel, O. et al. A myristoyl\/phosphotyrosine switch regulates c-Abl. Cell 112, 845\u2013857 (2003).","journal-title":"Cell"}],"container-title":["Nature Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nchembio.775.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nchembio.775","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nchembio.775.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T19:52:01Z","timestamp":1684439521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nchembio.775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,29]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["BFnchembio775"],"URL":"https:\/\/doi.org\/10.1038\/nchembio.775","relation":{},"ISSN":["1552-4450","1552-4469"],"issn-type":[{"value":"1552-4450","type":"print"},{"value":"1552-4469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,29]]}}}